Testing a new drug added to standard lymphoma treatment

Plain-English translation of NCT06496308 on ClinicalTrials.gov ↗ · Source last updated July 2024 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing whether adding to two standard cancer drugs ( and ) works better than the standard two-drug treatment alone for people with mantle cell lymphoma. Mantle cell lymphoma is an aggressive blood cancer, and this study includes patients who are not candidates for a stem cell transplant. The goal is to see if this combination improves how many patients achieve complete remission and how long they stay cancer-free.

Mantle cell lymphoma is difficult to treat, especially in patients who cannot have a stem cell transplant. Researchers believe that adding this medication might help more patients respond better to treatment and live longer without their cancer coming back.

Do you qualify?

You likely qualify if…

you have been diagnosed with mantle cell lymphoma and have not received any prior cancer treatment
you are at least 18 years old
your cancer is stage II through IV, or stage II with symptoms requiring treatment
you have at least one measurable tumor that doctors can track
you are not a candidate for autologous stem cell transplantation (a type of bone marrow transplant)
your blood counts and liver and kidney function are at acceptable levels for treatment

You likely don't qualify if…

you have previously taken BTK inhibitor drugs (a class of cancer medications)
you have serious infections, uncontrolled heart disease, or blood clotting disorders
you have an active infection that requires ongoing treatment with antibiotics, antifungals, or antivirals
you are HIV-positive
you have a mental health condition or other reason that would prevent you from following the study plan

What participation looks like

If you join this trial, you will be randomly assigned to receive either the standard two-drug treatment or the standard treatment plus the new medication. The treatment phase lasts about 6 months, with drugs given intravenously and some taken by mouth at home. After that, depending on your cancer's characteristics, you may continue on a maintenance treatment for up to 2 years. You will have regular clinic visits for blood tests, scans, and check-ups to monitor how well the treatment is working and any side effects.

AI-generated summary from trial data · Jun 4, 2026 · Not medical advice

Trial locations(1 site)

China

Ruijin Hospital, Shanghai